INGENOL MEBUTATE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for INGENOL MEBUTATE (INGENOL MEBUTATE).
Ingenol mebutate is a macrocyclic diterpene ester that induces rapid, mitochondria-dependent cell death (necrosis) in dysplastic keratinocytes upon topical application. It also activates protein kinase C (PKC) isoforms, specifically PKCδ, leading to mitochondrial dysfunction and release of pro-apoptotic factors. Additionally, it stimulates a local immune response via neutrophil-mediated oxidative burst and antibody-dependent cellular cytotoxicity.
| Metabolism | Ingenol mebutate is rapidly metabolized in the skin by esterases to its active metabolite, ingenol. Systemic absorption is minimal, and the drug is not significantly metabolized by hepatic CYP450 enzymes. |
| Excretion | Primarily hepatobiliary excretion into feces; minimal renal elimination (<1% unchanged). |
| Half-life | Terminal half-life approximately 18–24 hours; supports twice-daily application for actinic keratosis treatment. |
| Protein binding | >99% bound to plasma proteins, primarily albumin and alpha-1-acid glycoprotein. |
| Volume of Distribution | Not applicable (topical); negligible systemic absorption. Following IV administration in animals: Vd ~1.5 L/kg, suggesting extensive tissue distribution. |
| Bioavailability | Topical: <0.1% systemically absorbed; not administered orally. |
| Onset of Action | Local application: Clinical response (erythema, scaling) begins within 2–4 weeks of topical therapy. |
| Duration of Action | Effects persist for 4–8 weeks post-treatment; clearance of lesions may continue for up to 12 weeks. |
0.05% gel applied topically to the lesion once daily for 2 consecutive days per treatment course; repeat after 3 weeks if needed.
| Dosage form | GEL |
| Renal impairment | No dosage adjustment required for renal impairment. |
| Liver impairment | No dosage adjustment required for hepatic impairment. |
| Pediatric use | Not recommended for use in pediatric patients aged <18 years due to lack of safety and efficacy data. |
| Geriatric use | No specific dosage adjustment required; use with caution in elderly patients due to increased risk of skin irritation. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for INGENOL MEBUTATE (INGENOL MEBUTATE).
| Breastfeeding | No data on excretion in human milk; M/P ratio unknown. Due to potent irritant and cytotoxic properties, use is contraindicated during breastfeeding. Discontinue breastfeeding or avoid use. |
| Teratogenic Risk | No human data; animal studies not available. Avoid in pregnancy due to potential for systemic absorption and unknown effects. First trimester: theoretical risk of teratogenicity based on mitogenic activity. Second/third trimester: risk of preterm labor or fetal toxicity from systemic effects. |
■ FDA Black Box Warning
No FDA boxed warning exists for ingenol mebutate.
| Serious Effects |
["Hypersensitivity to ingenol mebutate or any component of the formulation.","Pregnancy (Category C; limited data, potential for fetal harm).","Lactation (not recommended due to potential risk to infant)."]
| Precautions | ["Severe local skin reactions (e.g., ulceration, crusting, vesiculation) may occur and require treatment interruption.","Avoid application to broken skin, open wounds, or areas of inflammation.","Do not apply to the perioral or perianal area, or to the eyelids, lips, or nostrils.","Contact with eyes should be avoided; may cause severe eye irritation.","Increased risk of photosensitivity; avoid sun exposure on treated areas.","Not indicated for internal use; for topical use only."] |
Loading safety data…
| Fetal Monitoring |
| Monitor maternal application site for severe reactions. In case of accidental ingestion, monitor for gastrointestinal and systemic toxicity. No specific fetal monitoring required with topical use. |
| Fertility Effects | No human data on fertility effects. In animal studies, no adverse effects on fertility reported with topical application. Systemic toxicity may impair reproductive function. |